DESTINY Calls For Daiichi Sankyo/AZ’s Enhertu In Other Indications
Gastric, Lung And Colorectal Data Promising
Executive Summary
Daiichi Sankyo and AstraZeneca’s ambitions to expand the use of their HER-2 targeted antibody-drug conjugate product beyond breast cancer are looking realizable on the back of new results presented at ASCO, but toxicities remain an issue.
You may also be interested in...
Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.
Shock As AstraZeneca’s Oncology R&D Head José Baselga Dies
AstraZeneca’s CEO Pascal Soriot confirmed the death of distinguished cancer researcher and head of its oncology R&D unit, José Baselga, on 21 March.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker